Your browser is no longer supported. Please, upgrade your browser.
Settings
ACHN Achillion Pharmaceuticals, Inc. daily Stock Chart
ACHN [NASD]
Achillion Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own0.15% Shs Outstand138.24M Perf Week-1.92%
Market Cap635.90M Forward P/E- EPS next Y-0.78 Insider Trans0.00% Shs Float138.24M Perf Month66.06%
Income-70.90M PEG- EPS next Q-0.16 Inst Own82.80% Short Float6.11% Perf Quarter60.28%
Sales- P/S- EPS this Y18.30% Inst Trans0.49% Short Ratio5.36 Perf Half Y87.76%
Book/sh1.67 P/B2.75 EPS next Y-26.20% ROA-26.30% Target Price8.00 Perf Year81.82%
Cash/sh1.69 P/C2.72 EPS next 5Y17.58% ROE-27.60% 52W Range1.29 - 5.03 Perf YTD189.31%
Dividend- P/FCF- EPS past 5Y4.10% ROI- 52W High-5.96% Beta1.52
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low266.67% ATR0.32
Employees56 Current Ratio14.60 Sales Q/Q- Oper. Margin- RSI (14)65.97 Volatility6.22% 9.90%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.70% Profit Margin- Rel Volume1.09 Prev Close4.60
ShortableYes LT Debt/Eq0.00 EarningsAug 14 BMO Payout- Avg Volume1.57M Price4.73
Recom1.50 SMA204.80% SMA5037.45% SMA20065.10% Volume161,107 Change2.83%
May-21-18Upgrade Barclays Underweight → Equal Weight $5
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3.50
Sep-12-17Reiterated Ladenburg Thalmann Buy $9 → $6.50
Aug-10-17Downgrade Robert W. Baird Outperform → Neutral $5
Aug-09-17Reiterated Chardan Capital Markets Neutral $5 → $4
May-18-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-02-17Initiated Ladenburg Thalmann Buy $10
Nov-04-16Upgrade Chardan Capital Markets Sell → Neutral $5
Sep-23-16Reiterated Chardan Capital Markets Sell $4 → $5
Sep-23-16Initiated Wedbush Outperform $13
Sep-15-16Initiated FBR & Co. Outperform $16
Jul-14-16Initiated Chardan Capital Markets Sell $4
Jul-07-16Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-26-16Upgrade Robert W. Baird Neutral → Outperform $10
Feb-25-16Reiterated Maxim Group Buy $11 → $8
Sep-09-15Initiated Jefferies Hold
Aug-13-15Reiterated Maxim Group Buy $19 → $11
May-20-15Reiterated Leerink Partners Outperform $25 → $16
May-20-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-10-15Reiterated Maxim Group Buy $22 → $19
Aug-09-19 08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
Aug-08-19 07:30AM  Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +8.56%
Jul-26-19 05:29PM  Why Achillion Pharmaceuticals Stock Flew Higher Again Today Motley Fool +18.02%
Jul-23-19 12:30PM  Why Achillion Pharmaceuticals Stock Is Soaring Again Today Motley Fool +28.88%
Jul-22-19 05:50PM  Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today Motley Fool +16.39%
03:41PM  Why Achillion Pharmaceuticals Stock Jumped Today Motley Fool
07:00AM  Achillions ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers GlobeNewswire
Jul-17-19 06:00AM  Achillion Pharmaceuticals ACHN- 2019 Top Picks' Mid-Year Update MoneyShow
Jul-10-19 09:23AM  Does Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Have A High Beta? Simply Wall St.
Jul-04-19 08:35AM  Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks
Jun-28-19 08:45AM  Alexion Receives FDA Approval for Label Expansion of Soliris Zacks
Jun-26-19 06:29PM  Heres What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN) Insider Monkey
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-13-19 07:00AM  Achillion to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-10-19 07:00AM  Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-08-19 09:30AM  Why Is Achillion (ACHN) Down 1.4% Since Last Earnings Report? Zacks
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
07:00AM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting GlobeNewswire
May-14-19 06:00AM  Achillion Granted Twentieth Patent for Factor D Portfolio GlobeNewswire +7.66%
May-13-19 09:13AM  Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1 Zacks -5.84%
May-11-19 08:40AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
May-09-19 04:00PM  What You Need to Know About Achillion Pharmaceuticals' Q1 Update Motley Fool
10:19AM  Achillion: 1Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports First Quarter 2019 Financial Results GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-06-19 09:30AM  Why Is Achillion (ACHN) Up 25.6% Since Last Earnings Report? Zacks
Apr-04-19 10:23AM  Achillion Meets Enrollment Target in Kidney Disease Studies Zacks
Apr-03-19 12:50PM  Why Achillion Pharmaceuticals Stock Is Jumping Today Motley Fool
06:00AM  Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy GlobeNewswire
Mar-28-19 04:41PM  Achillion Completes Enrollment in Rare Blood Disorder Study Zacks
Mar-27-19 06:00AM  Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial GlobeNewswire
Mar-13-19 01:09PM  Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Are Analysts Right About The Drop In Earnings? Simply Wall St.
Mar-08-19 10:04AM  Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4 Zacks
06:00AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-07-19 06:00AM  Achillion Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-21-19 12:57PM  Why a Connecticut pharma firm moved its C-suite to Blue Bell American City Business Journals
06:00AM  Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market GlobeNewswire
Feb-19-19 06:00AM  Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference GlobeNewswire
Feb-12-19 07:50AM  Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-11-19 06:00AM  Achillion Appoints Brian Di Donato as Chief Financial Officer GlobeNewswire
Feb-04-19 12:45PM  Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up Zacks
Jan-31-19 06:00AM  Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers GlobeNewswire
Jan-29-19 11:10AM  Alexion's Ultomiris Meets Primary Endpoint in aHUS Study Zacks
Jan-10-19 10:49AM  Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December Motley Fool
05:00AM  Top Picks 2019- Achillian Pharmaceuticals ACHN MoneyShow
Jan-03-19 07:36AM  The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen Benzinga
06:00AM  Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors GlobeNewswire
Dec-31-18 10:50AM  4 Healthcare Stocks That Are Raising Eyebrows ACCESSWIRE +7.43%
Dec-20-18 04:30PM  Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day Motley Fool -19.51%
Dec-19-18 03:45PM  Why Achillion Pharmaceuticals Sank Again Today Motley Fool -15.90%
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks -18.75%
04:33PM  Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today Motley Fool
03:02PM  Why Achillion Pharmaceuticals Is Cratering Again Today Motley Fool
08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga
06:50AM  Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals ACCESSWIRE
Dec-17-18 04:33PM  Why Achillion Pharmaceuticals Crashed Today Motley Fool -22.83%
04:02PM  Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update GlobeNewswire
Dec-16-18 02:18PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-12-18 01:15AM  Should You Buy Achillion Pharmaceuticals, Inc. (ACHN)? Insider Monkey
Dec-10-18 06:00AM  Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018 GlobeNewswire
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-03-18 09:00AM  Implied Volatility Surging for Achillion (ACHN) Stock Options Zacks +7.96%
Nov-07-18 06:30AM  Achillion: 3Q Earnings Snapshot Associated Press
06:00AM  Achillion Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-18-18 01:14PM  Does Achillion Pharmaceuticals Inc (NASDAQ:ACHN) Have A Volatile Share Price? Simply Wall St.
Oct-17-18 07:40AM  Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries Discovering Underlying Factors of Influence GlobeNewswire
Sep-25-18 06:00AM  Achillion to Present at the Leerink Partners Roundtable Series GlobeNewswire
Sep-14-18 09:09AM  The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion Zacks
Sep-13-18 09:14AM  IPOs and Foreign Investment Propel Biotech: 4 Top Picks Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Sep-07-18 09:30AM  Why Is Achillion (ACHN) Up 24.7% Since Last Earnings Report? Zacks
Aug-31-18 04:14AM  Achillion Pharmaceuticals (ACHN) Shares March Higher, Can It Continue? Zacks +8.49%
Aug-30-18 06:00AM  Achillion to Present at the Baird 2018 Global Healthcare Conference GlobeNewswire
Aug-23-18 11:39AM  7 Cheap Biotech Stocks to Buy Now InvestorPlace
Aug-20-18 08:20AM  Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-15-18 04:05PM  Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer GlobeNewswire
Aug-08-18 07:30PM  Achillion: 2Q Earnings Snapshot Associated Press
04:05PM  Achillion Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-11-18 11:05AM  Achillion's 3rd Factor D Inhibitor Enters Clinical Studies Zacks
Jul-10-18 06:05AM  Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D GlobeNewswire
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-22-18 08:18AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. Motley Fool
Jun-14-18 06:05AM  Achillion to Present at the 2018 JMP Securities Life Sciences Conference GlobeNewswire
Jun-01-18 10:40AM  Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound? Zacks
07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
May-31-18 08:32AM  Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert Zacks
May-21-18 01:56PM  SMid-Cap Biotech: Barclays Downgrades Prothena, Upgrades Achillion Benzinga
07:40AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
May-11-18 06:05AM  Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress GlobeNewswire
May-04-18 07:35AM  Wired News -Esperion Reported Positive Top-line Results from Late Stage Safety Study of its Cholestrol Drug - Bempedoic Acid ACCESSWIRE
06:35AM  Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
May-03-18 10:27AM  Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO Zacks
May-02-18 09:09AM  Achillion: 1Q Earnings Snapshot Associated Press
06:35AM  Achillion Reports First Quarter 2018 Financial Results and Management Transition GlobeNewswire
Apr-09-18 08:30AM  Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V Discovering Underlying Factors of Influence GlobeNewswire
Mar-20-18 08:37AM  Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock? Zacks
Mar-14-18 02:58PM  Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now Insider Monkey
Mar-13-18 07:35AM  Report: Developing Opportunities within Mimecast, Mazor Robotics, JD, Achillion Pharmaceuticals, Kulicke and Soffa Industries, and Weibo Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-08-18 06:05AM  Achillion to Present at the Barclays Global Healthcare Conference GlobeNewswire +7.80%
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scheer DavidDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:24 PM
VAN NOSTRAND ROBERT LDirectorDec 14Option Exercise1.0520,00021,00020,000Dec 18 04:22 PM